Dermata Therapeutics, Inc. (NASDAQ:DRMA – Get Free Report) was up 5.2% during mid-day trading on Thursday . The stock traded as high as $2.37 and last traded at $1.42. Approximately 76,088,712 shares traded hands during trading, an increase of 6,629% from the average daily volume of 1,130,804 shares. The stock had previously closed at $1.35.
Dermata Therapeutics Stock Down 16.9 %
The stock has a market capitalization of $2.41 million, a P/E ratio of -0.07 and a beta of 0.65. The firm’s 50 day simple moving average is $1.21 and its two-hundred day simple moving average is $1.31.
About Dermata Therapeutics
Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.
Featured Articles
- Five stocks we like better than Dermata Therapeutics
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- MarketBeat Week in Review – 03/24 – 03/28
- The 3 Best Blue-Chip Stocks to Buy Now
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
